Facilities

ten23 health expands Swiss sterile drug product manufacturing site

29-Mar-2022 By Rachel Arthur

CDMO ten23 health is further expanding its drug product manufacturing site in Visp, Switzerland.

CytoImmune Therapeutics opens clinical cell manufacturing facility in Puerto Rico

28-Mar-2022 By Rachel Arthur

CytoImmune Therapeutics, a clinical-stage immunotherapy company developing a novel class of engineered natural killer (NK) cell-based cancer therapies, has announced the opening of its clinical cell manufacturing facility in Toa Baja, Puerto Rico.

Vaccine and gene therapy focused CDMO secures GMP certification for Belgian site

25-Mar-2022 By Jane Byrne

Exothera, a CDMO specializing in the industrialization of vaccine and gene therapy processes, reports that it has achieved GMP certification for its facilities in Jumet, Belgium.

Moderna’s Australian mRNA manufacturing facility set to become operational in 2024

24-Mar-2022 By Rachel Arthur

Moderna has finalized a strategic partnership with the Australian government to build an mRNA manufacturing facility in Melbourne: which is expected to produce up to 100 million mRNA respiratory vaccine doses annually.

Palo Alto CDMO boosts induced pluripotent stem cell manufacturing capacity

17-Mar-2022 By Jane Byrne

A California based biotech has tripled its capacity to manufacture GMP grade induced pluripotent stem cells (iPSC) space through the expansion of its contract development and manufacturing (CDMO) facility.

Novartis inks contract manufacturing deal with Carisma

15-Mar-2022 By Jane Byrne

Novartis continues down the third-party manufacturing route, as it secures an agreement with Carisma Therapeutics, a firm developing a cell therapy platform focused on engineered macrophage-based therapeutics.

Production starts at new Cytiva manufacturing facility in Wales

10-Mar-2022 By Rachel Arthur

Global life sciences company Cytiva is opening a new 11,000 m² manufacturing facility in Cardiff, Wales.

Stevanato Group to create manufacturing hub in China to support biologics growth

10-Mar-2022 By Rachel Arthur

Stevanato Group has acquired a facility in Zhangjiagang as part of its expansion in China.

Flow Eighteen38 to double protein purification capacity

08-Mar-2022 By Rachel Arthur

Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, has announced a €5m ($5.58m) investment into its protein production and biophysical characterization capabilities...

Moderna to build mRNA manufacturing site in Kenya

08-Mar-2022 By Rachel Arthur

mRNA pioneer Moderna has entered into a Memorandum of Understanding with the Government of the Republic of Kenya to establish an mRNA manufacturing facility in the country.

Charles River expanding plasmid DNA and viral vector development in Europe

07-Mar-2022 By Jane Byrne

Charles River recently announced the expansion of its plasmid DNA and viral vector development and manufacturing capabilities in Europe; it says the move is to support the growing need of customers and to safeguard future supply.

WHO establishes global biomanufacturing training hub in Korea

25-Feb-2022 By Rachel Arthur

A global biomanufacturing training hub will be established in Korea to serve low- and middle-income countries wishing to produce biologicals such as vaccines, insulin, monoclonal antibodies and cancer treatments.

Valneva revives Scottish vaccine manufacturing plans

22-Feb-2022 By Rachel Arthur

Valneva has been awarded up to £20m ($27m) in R&D funding from Scottish Enterprise: which will be used to revive its plans to increase vaccine manufacturing in Scotland.

Egypt, Kenya, Nigeria, Senegal, South Africa and Tunisia to establish mRNA vaccine production

21-Feb-2022 By Jane Byrne

Last week saw the WHO announce the first six countries that will receive the technology needed to produce mRNA vaccines on the African continent, as part of the global mRNA technology transfer hub project.

Biologics CDMO market is expanding rapidly but is challenged by capacity constraints

15-Feb-2022 By Jane Byrne

The biologics CDMO market is expected to grow by US$8.65bn from 2021 to 2026, at a CAGR of 12.2% during the forecast period, according to new market data from Technavio.

Piramal Pharma Solutions invests $75m in UK ADC and API facilities

10-Feb-2022 By Rachel Arthur

CDMO Piramal Pharma Solutions will expand capabilities of its Antibody-Drug Conjugate (ADC) facility in Grangemouth, Scotland; and invest in new Active Pharmaceutical Ingredient (API) infrastructure at its Morpeth, England facility.

Polyplus acquires French company enabling customized DNA vectors

03-Feb-2022 By Jane Byrne

Polyplus, a provider of transfection reagents, has acquired e-Zyvec, a France-based provider of DNA design and production services for tailor-made DNA vectors to expand expertise in plasmid DNA vector engineering.

US modular cleanroom systems supplier invests over $14m in new manufacturing hub

03-Feb-2022 By Jane Byrne

AES Clean Technology, a supplier of cleanroom facilities for the pharmaceutical and biopharmaceutical sectors, is ploughing $14.2m into a new US manufacturing facility.

Recipharm acquires Portuguese CDMO as it looks to grow its biologics business

01-Feb-2022 By Jane Byrne

Contract development and manufacturing organization (CDMO), Recipharm, has acquired GenIbet, a Portuguese CDMO, specializing in the manufacture of biological clinical trial material.

New cell therapy focused CDMO has San Diego blood bank origins

31-Jan-2022 By Jane Byrne

A new California based CDMO has been launched, one that is focused on supporting cell therapy developers.

Recipharm leverages BSF capabilities at French site, secures vaccine packaging deal

28-Jan-2022 By Jane Byrne

Contract development and manufacturing organization (CDMO), Recipharm, says it has inked a deal with a top 10 big pharma company to support vaccine manufacturing from its facility in Kaysersberg, France.

JP Morgan Healthcare Conference 2022

Korea’s Samsung Bio reveals massive capacity boost on the cards

13-Jan-2022 By Jane Byrne

Samsung Biologics flags further facility construction plans, with biologics, cell and gene therapies and next-generation vaccines to be the focus of those new sites.

Protagen, BioAnalytix, and GeneWerk unveil combined CRO business: ProtaGene

13-Jan-2022 By Jane Byrne

Protagen, BioAnalytix, and GeneWerk this week announced their unified operations and re-brand as ProtaGene, a CRO partner for the biologics and cell and gene therapy developers, from discovery to commercialization.

UK market developments: GHO Capital invests in RoslinCT, Symbiosis expands viral therapy capabilities

11-Jan-2022 By Jane Byrne

Healthcare investors, GHO Capital Partners LLP, have invested in Scotland based, RoslinCT, a contract development and manufacturing organization (CDMO) focused on advanced cell therapies.

Wheeler Bio looks to solve tech transfer challenges, raises $14m in seed funding

11-Jan-2022 By Jane Byrne

Wheeler Bio, a newly established company aiming accelerate the translation of therapeutic innovation into clinical impact, recently closed a US$14m seed financing round.

Novo Holdings acquires blow-fill-seal manufacturing specialist Ritedose

10-Jan-2022 By Jane Byrne

Life science investor group, Novo Holdings, has agreed to buy Ritedose, the largest sterile CDMO in the US focused on advanced blow-fill-seal technology, from Hong-Kong based, AGIC Capital, and China’s Humanwell.

G42 and Mubadala to establish biopharma manufacturing campus in Abu Dhabi

03-Jan-2022 By Jane Byrne

Abu Dhabi-based entities, the sovereign wealth fund, Mubadala Investment Company, and AI and cloud computing specialist, G42, are to set up a biopharma campus there; the move is aimed at bolstering biopharma linked innovation, R&D and manufacturing...

What are the prospects for the US gene therapy industry in 2022?

22-Dec-2021 By Jane Byrne

There is a healthy appetite for continued investment in gene therapy, in new modalities and more indications, says an industry insider as he reflected on the prospects for the US gene therapy sector next year.

Deloitte: Artificial intelligence technology investments prove top priority for biopharma leaders

22-Dec-2021 By Jane Byrne

The pandemic has focused biopharma industry minds on digital innovation, finds a Deloitte report.

Fujifilm Diosynth in $300m expansion of largest single-use facility in North America

20-Dec-2021 By Ben Hargreaves

The investment comes as part of a wider $850m global expansion by parent company Fujifilm Corporation of its biologics CDMO subsidiary.

SGS acquires live biotherapeutics focused CDMO

14-Dec-2021 By Jane Byrne

SGS, the Swiss-based testing, inspection and certification company, has acquired Quay Pharma, a UK based pharmaceutical industry targeted contract development and manufacturing organization (CDMO).

Moderna to build mRNA vaccine manufacturing facility in Australia

14-Dec-2021 By Rachel Arthur

Moderna and the Australian government have announced an agreement in principle to build a mRNA vaccine manufacturing facility in Victoria, Australia: providing up to 100 million doses a year.

CDMO opens microbial-based therapeutics and mRNA vaccines facility in South Australia

13-Dec-2021 By Jane Byrne

This month saw BioCina officially open its new biologics manufacturing facility in Adelaide, Australia, flagging it as the only TGA, EMA, Health Canada and US-FDA approved commercial facility of its kind in the country.

Tech transfer box ticked in Catalent and BrainStorm cell therapy alliance

09-Dec-2021 By Jane Byrne

Catalent is reporting that the technology transfer for the manufacture of BrainStorm Cell Therapeutics’ autologous cellular therapy at its facility in Houston, Texas has been finalized.

New Fujifilm site will cater to cell culture media market demands in China

07-Dec-2021 By Jane Byrne

Fujifilm Irvine Scientific, Inc, is to build a new bioprocessing center in China, with the goal of ensuring local cell culture media optimization support for vaccines, advanced therapies, and biotherapeutic drug development.

Operations begin at new Genezen lentiviral and retroviral vector lab in Indianapolis

06-Dec-2021 By Jane Byrne

Genezen, a cell and gene therapy focused CDMO, has just opened a new process development and analytical lab, a build that represents the first phase of a 75,000+ square foot cGMP-compliant lentiviral and retroviral vector production facility in Indianapolis.

CDMO deals roundup: AGC Biologics, Halix and BioConnection support monoclonal antibody, gene therapy and vaccine projects

02-Dec-2021 By Jane Byrne

Several contract development and manufacturing organization (CDMO) supported biopharma projects have been flagged in the past month. We take a closer look.

Long lead times: Demand currently outstrips supply for contract manufacturing

30-Nov-2021 By Jane Byrne

As capital project delivery ramps back up to pre-pandemic levels over the coming months and years, the smaller biopharma players are looking outside their own resources for strategic manufacturing and research support, confirms a new market outlook from...

Speed, flexibility and innovation: Rethinking the way the biopharma industry operates

29-Nov-2021 By Jane Byrne

A new report reveals that “speed-to-market” has jumped up from a lower-ranking business driver before the pandemic to the top priority today for biopharma companies, overtaking cost-based considerations by a healthy margin.

SK investment set to bolster CBM, bring capacity to a ‘starved CGT’ marketplace

25-Nov-2021 By Jane Byrne

Korean company, SK, is investing in the Philadelphia-based Center for Breakthrough Medicines (CBM), a move that will support the US company in its bid to become the world's largest end-to-end cell and gene therapy contract development and manufacturing...

AstraZeneca opens new advanced therapeutics R&D facility in Cambridge

23-Nov-2021 By Jane Byrne

AstraZeneca has built a new R&D facility - The Discovery Centre (DISC) - in Cambridge in the UK.

Increased demand for CDMO microbial outsourcing services

18-Nov-2021 By Jane Byrne

Biotech innovators are looking to CDMOs for their key microbial expertise in order to move their therapies from lab to the market, says Lonza.

Alleviating CGT bottlenecks: Standards needed to ensure volumes, quality of starting material

12-Nov-2021 By Jane Byrne

Be the Match BioTherapies (BTMB) says it is critical that resilient cell sourcing infrastructures exist when cell and gene therapies (CGT) surge to market.

Special Edition: BioPharma Hubs

New Jersey cementing status as US manufacturing hub

10-Nov-2021 By Ben Hargreaves

The state houses several life sciences companies, with the leading number of manufacturing facilities in the country.

Special Edition: Biopharma Hubs

Singapore provides access to ‘top global talent’, says 10x Genomics

10-Nov-2021 By Ben Hargreaves

The company recently opened a manufacturing and commercial hub in Singapore, making the facility its first outside of the US.

Special Edition: BioPharma Hubs

Dublin set to get a life sciences incubation and acceleration cluster

10-Nov-2021 By Jane Byrne

A new specialized lab, office and collaboration space for over 100 life science and health technology professionals, entrepreneurs, and researchers was recently announced for The Campus, Cherrywood in South Dublin, Ireland.

Edinburgh BioQuarter looks to create £1bn health innovation district

10-Nov-2021 By Rachel Arthur

Edinburgh BioQuarter has formally launched its public procurement process for a private sector partner to develop the health innovation hub.

bluebird bio plans ‘new nest’ around hybrid work model

05-Nov-2021 By Rachel Arthur

bluebird bio has signed a long-term lease for a 61,000 square foot facility at Assembly Row, Greater Boston: saying the new headquarters has been designed to reflect modern ways of working and deliver significant cost savings.

Lonza invests in exosome category, acquires development and manufacturing capabilities

04-Nov-2021 By Jane Byrne

Lonza has been investing in developing exosome manufacturing and characterization technologies for the past five years, and this week it ramped up its focus on that category by acquiring two sites.

CPhI Worldwide

Continuous manufacturing rife with opportunity, challenges: Thermo Fisher

02-Nov-2021 By Jenni Spinner

During CPhI Worldwide, leaders from two organizations will outline how CM is taking off, potential benefits, and how to clear common obstacles to adoption.